TY - JOUR T1 - Triglycerides, HDL cholesterol and atherogenic dyslipidaemia in the 2019 European guidelines for the management of dyslipidaemias JO - Clínica e Investigación en Arteriosclerosis (English Edition) T2 - AU - Pedro-Botet,Juan AU - Ascaso,Juan F. AU - Blasco,Mariano AU - Brea,Ángel AU - Díaz,Ángel AU - Hernández-Mijares,Antonio AU - Pintó,Xavier AU - Millán,Jesús SN - 25299123 M3 - 10.1016/j.artere.2019.12.001 DO - 10.1016/j.artere.2019.12.001 UR - https://www.elsevier.es/en-revista-clinica-e-investigacion-arteriosclerosis-english-415-articulo-triglycerides-hdl-cholesterol-atherogenic-dyslipidaemia-S2529912320300620 AB - In general, both European and American clinical guidelines have addressed the management of atherogenic dyslipidaemia in an unconvincing and even superficial way, largely because of the available therapeutic limitations. Consequently, this type of dyslipidaemia is underdiagnosed, under-treated, and under-controlled. Given the recent presentation of the 2019 guidelines of the European Atherosclerosis Society and the European Society of Cardiology on the management of dyslipidaemias, it seems appropriate to examine its position with respect to atherogenic dyslipidaemia and/or its main components, the increase in triglyceride-rich lipoproteins, and the decrease of high-density lipoprotein cholesterol. ER -